EverPoint Asset Management’s Neurocrine Biosciences NBIX Stock Holding History

EverPoint Asset Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$2.71M	Buy	+70,000	New	+$3.17M	0.05%	308
2015 Q3	–	Sell	-150,000	Closed	-$7.16M	–	497
2015 Q2	$7.16M	Sell	150,000 -15,000	-9%	-$636K	0.13%	223
2015 Q1	$6.55M	Buy	+165,000	New	+$5.9M	0.12%	228

Other funds holding NBIX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

EverPoint Asset Management's NBIX Position: Q4 2016 in Review

EverPoint Asset Management opened a new position in Neurocrine Biosciences (NBIX) in Q4 2016: 70,000 shares worth $2.71M. The stake represents 0.05% of the portfolio and ranks #308 among its holdings. This is a return to the name: EverPoint Asset Management previously reported a position in NBIX as recently as Q2 2015.

EverPoint Asset Management first reported a position in NBIX in Q1 2015 and has held it in 3 quarters since. The position peaked at $7.16M in Q2 2015. 225 funds tracked by Wall St. Rank hold NBIX as of Q4 2016.

EverPoint Asset Management held 70,000 shares of Neurocrine Biosciences worth $2.71M as of Q4 2016.
Neurocrine Biosciences was a new EverPoint Asset Management position in Q4 2016.
Neurocrine Biosciences made up 0.05% of EverPoint Asset Management's portfolio in Q4 2016, its #308 holding.
EverPoint Asset Management first reported a position in Neurocrine Biosciences in Q1 2015 and has held it in 3 quarters since.
EverPoint Asset Management's Neurocrine Biosciences position peaked at $7.16M in Q2 2015.
225 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2016.

Based on EverPoint Asset Management's 13F filing for Q4 2016, filed 14 Feb 2017.